大剂量沐舒坦对老年重症肺炎的疗效观察

目的 探讨大剂量沐舒坦静滴治疗老年性重症肺炎的临床疗效.方法 随机将符合诊断老年性重症肺炎病例60例分为治疗组和对照组各30例,两组均予以机械通气、解痉、抗感染及营养支持等常规治疗,对照组予以常规沐舒坦(30 mg Q8 H)静脉推注,治疗组予以大剂量沐舒坦(500 mg Q12 H)静脉滴注,治疗前、治疗后7天分析所有入选病例临床症状、血气、血常规等指标改善情况及不良反应发生情况.结果 治疗组在临床综合疗效,症状体征改善及实验室指标改善方面均明显优于对照组(P(0.05),且不良反应发生率较低.结论 早期长程的大剂量沐舒坦对老年重症肺炎是安全有效的,可以阻止病情进一步加重.

Effect of High-dose Mucosolvan Applied to the elderly Patients with Severe Pneumonia

Objective To study the effects of the high-dose mucosolvan on the elderly patients with severe pneumonia. Methods 60 elder patients with severe pneumonia were randomly divided into two groups. The treatment group was administered continuous intravenous drip of high-dose mucosolvan (500 mg each time, two times a day for 7 days), and the control group was administered continuous intravenous drip of routine-dose mucosolvan (30 mg each time, three times a day for 7 days). Both groups were applied to oxygen, eliminate sputum and antibiotics. The blood gas, clinical symptoms and signs were analyzed. Results The clinical manifestations and blood gas analysis in the treatment group were better than the control group (P <0.05). Conclusions High-dose mucosolvan on elderly patients with severe pneumonia earlier is safe and effective, which can prevent the diasese from worsening, and deserves clinical application.